Eli Lilly’s Foundayo prescription launch has drawn close attention from investors after the company’s newly approved oral weight-loss pill recorded 1,390 U.S. prescriptions in its first week, according to analysts citing IQVIA data. The early figures suggest Lilly is gaining initial traction as the race for the obesity drug market expands beyond blockbuster injections.
Foundayo, the brand name for orforglipron, won U.S. approval on April 1, 2026. Lilly said prescriptions were accepted immediately through LillyDirect, shipping began on April 6, and broader retail pharmacy and telehealth availability started on April 9.
That timeline helps explain why analysts treated the first prescription snapshot cautiously. IQVIA data for the week ended April 10 may reflect only about two days of broad capture, not a full week of nationwide demand.
Foundayo Prescription Launch Starts Under Close Watch
Analysts have framed the first numbers as encouraging, even if they remain incomplete. Jefferies analyst Akash Tewari described the opening script count as excellent, while Lilly itself cautioned that the early weekly figures may not capture the full breadth of pharmacy partners and should be interpreted over time rather than as a complete count.
RBC Capital Markets analyst Trung Huynh said weeks 8 through 12 would likely offer the earliest meaningful window for judging Foundayo’s true commercial momentum. That means the launch is off to a watched start, but not yet a settled one.
Foundayo Enters A Fast-Growing Oral Obesity Drug Race
The rollout comes as competition sharpens between Eli Lilly and Novo Nordisk for a bigger share of the obesity treatment market. Novo’s Wegovy pill reached 3,071 U.S. prescriptions in its first four days after launch on January 5, offering an early benchmark for comparison.
Oral Wegovy was prescribed 113,354 times in the same week, up from 105,366 in the prior week. Analysts cited there said the market appears to be expanding rather than simply shifting patients away from Lilly’s injectable Zepbound.
That matters because oral drugs could widen access to obesity treatment among patients who want more convenience or prefer pills over injections.
Lilly Sees Convenience As A Key Selling Point
Lilly has positioned Foundayo as a more convenient option for some patients. On its official product materials, the company says the once-daily oral GLP-1 can be taken any time of day without food or water restrictions.
Lilly CEO David Ricks said pills may appeal to patients who want to “graduate” from injectables after reaching their weight-loss goals. At the same time, he acknowledged that the pill is not as strong as Zepbound or Mounjaro, but can still meet the needs of many people.
Read: Tirzepatide Vs Semaglutide Study Raises Lean Mass Questions
For now, Foundayo’s launch offers an early look at how oral GLP-1 drugs may perform as companies move further into cash-pay and direct-to-consumer models. The first script count shows interest, but it does not yet define long-term success.
What happens over the next two to three months will likely matter far more than the opening week. That is when analysts expect a clearer read on whether Foundayo can turn launch buzz into durable commercial momentum.
